by Comite Web | Nov 15, 2022
The activity of the research group led by Dr. Joaquín Arribas focuses on the development of new immunotherapies against cancer and on studying the mechanisms of resistance to targeted therapies. To this end, the group has multiple tools at its disposal, including murine models derived from cancer patients. The use of these models allows the entire translation process to be carried out, from the identification of the altered target, the development and preclinical study of the efficacy of the new therapy, to the evaluation of the possible resistance mechanisms developed by the tumor against the new drug.
The three main lines of research are:
- Immune redirection against solid tumors: development of strategies based on chimeric antigen receptors (CARs).
- Resistance to immune redirection: study of the molecular mechanisms associated with the resistances that develop in response to immunotherapies and their possible solutions.
- Immune redirection and senescence: study of the molecular mechanisms involved in the interaction between senescence and tumor progression, mainly mediated by its effect on the immune system.
by Comite Web | Nov 15, 2022
This group includes two teams that carry out their research at the Hospital del Mar:
The group of “Ablation therapies in oncologic surgery“directed by Fernando BurdíoThe primary objective of the scientific production and technological innovation in the field of applications of high frequency currents in the generation of heat in biological tissues, aimed at local cell destruction, minimally invasiveof pathological tissues, especially (but not exclusively) of human neoplasms.
https://www.imim.cat/programesrecerca/cancer/es_thipertermia.html
The “Molecular Targets of Cancer” group led by Pilar Navarro (IIBB-CSIC/ Associated Unit Hospital del Mar Research Institute (HMRI)) has been exploring the molecular mechanisms of pancreatic cancer for more than 20 years with the aim of identifying new targets to improve early diagnosis and treatment of this tumor. For this purpose, we use cell and molecular biology techniques, in vitro functional assays and preclinical animal models that recapitulate the human pancreatic tumor and its microenvironment.
Our most recent studies are focused on Galectin-1. as a biomarker and new therapeutic immune checkpoint (Martínez-Bosch N et al. Oncotarget 2018; Martínez-Bosch N et al. Cancer Res. 2014; Orozco CA et al. PNAS 2018; Navarro P et al. Clin Cancer Res. 2020), sAXL as an early biomarker of pancreatic cancer and differential diagnosis of chronic pancreatitis (Martínez-Bosch N et al. eBioMed 2022) and the study of translational control as a new mechanism of gene reprogramming in this cancer (Ortiz-Zapater E et al. Nat Med. 2012; Villanueva E et al. Nat Comm. 2017; Jungfleisch J et al. Genome Res. 2017).
